On Thursday, May 23, C-Path's RDCA-DAP team joined Dr. Laurent Servais of the University of Oxford and the University of Liège, for an overview of Actimyo and relevant learnings from use cases across rare disorders spanning different degrees of complexity and readiness. Additionally, patient advocacy group leaders will speak to their experience based on stage of development and the ability of Actimyo to assess individuals with a neuromuscular disorder or non-NMDs (e.g., Duchenne muscular dystrophy, Angelman syndrome, and CTNNB1).
SUBSCRIBE to C-Path's KZfaq Channel Now ►► / criticalpathinstitute
FOLLOW C-Path:
►LinkedIn: / c-path
►Facebook: / cpathinstitute
►Twitter: CPathInstitute?re
About Critical Path Institute
C-Path is an independent, nonprofit established in 2005 as a public-private partnership, in response to the FDA’s Critical Path Initiative. C-Path’s mission is to lead collaborations that advance better treatments for people worldwide. Globally recognized as a pioneer in accelerating drug development, C-Path has established numerous international consortia, programs and initiatives that currently include more than 1,600 scientists and representatives from government and regulatory agencies, academia, patient organizations, disease foundations and pharmaceutical and biotech companies. With dedicated team members located throughout the world, C-Path’s global headquarters is located in Tucson, Arizona and C-Path’s Europe subsidiary is headquartered in Amsterdam, Netherlands. For more information, visit c-path.org.
#CPath #drugdiscovery #researchgrants #globalhealth #drugdevelopment #datasharing #researchfunding #raredisease #academicresearch #regulatoryscience #globalhealth #consortia #collaboration #FDA #EMA #T1D #Parkinsons #Alzheimers #PKD #Duchenne #ALS #biomarkers